ARGENICA THERAPEUTICS LIMITED IPO Analysis

From prospectus , Media articles , Management interviews and company presentation

ARGENICA THERAPEUTICS LIMITED

IPO PRICE 20c
Shares on Issue 73.1 Mil
Mcap 14.7 Mil
EV 7.7 Mil
Cash 7 Mil

Argenica Therapeutics to undertake the development and commercialisation of a novel drug known as ARG-007 developed by world-leading researchers at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron
Institute).

Argenica is developing “best in class” novel neuroprotective therapeutics that provide protection for brain cells that would otherwise potentially be irreparably damaged by stroke, and other types of brain injury.

The Argenica project has been in development for over 6 years, with significant capital spent through external grants and philanthropic funding.

ARG-007, Argenica’s lead candidate, is based on arginine rich peptides, which has proven neuroprotective properties and therefore can offer protection to the brain following stroke and other acute central nervous system injuries. Pre-clinical evidence has shown ARG-007 has efficacy in multiple models of stroke and other type of brain injury.

The Argenica solution is targeted at treating stroke, providing immediate or point of care intervention with neuroprotective therapeutic, ARG-007, aimed at significantly impacting patient recovery and long-term prognosis by reducing penumbral cell death.

Early intervention could reduce brain cell death during period prior to formal diagnosis and treatment of underlying stroke condition.

A small change in infarct volume or cell death can have very significant impact on patient life and outcomes.





NEUROPROTECTION & STROKE

• Stroke is one of the leading cause of mortality and disability worldwide, and there are substantial economic costs for post stroke care.
• In the event of stroke or other traumatic brain injury, brain cells suffer significant damage which in many cases is irreparable.
• There are currently no marketed treatments capable of protecting the brain from damage following stroke.
• Current stroke therapies target the underlying cause of ischaemic stroke without addressing further damage being done to brain tissue.
• Timely diagnosis and treatment is critical after a stroke as the brain ages approximately 3.6 years every hour that appropriate treatment is delayed

Conclusion :

Biotechs/ Medtechs IPOs has always been special to me. I did very well in a lot of them for short , medium and long term i.e. EMV , PAR, IXC , EX1 , TLX , NYR etc etc

Argenica is no different . Its priced at extremely low valuations and It is in a unique space as I explained above.

Worth Noting that ALTO capital is a lead manager in Argenica who floated some amazing Biotechs / Medtechs in the past i.e. EX1 , NYR and OSX .
Also Geoff Pocock ( Chairman) and Mac equities are involved with Argenica who did Emvision IPO which was floated at 25c .. EMV made a high of $ 4.30 this year and currently trading at $ 3

Argenica is Solving an unmet clinical need .Currently there are no safe, early intervention therapeutics capable of protecting the brain from damage following stroke, Argenica could become one of only a hand full of companies with a solution.
Preliminary data shows that Argenica’s lead candidate, ARG-007, reduces brain tissue death after a stroke.

Argenica also got an exceptional team with expertise in drug development commercialisation and capital markets

IMO it will open around 30c to 32c and with any updates regarding clinical trials or any early synergies with BIG pharma etc .. It will start trading above 50c .If there are successful in any of their clinical trials then it can truly become a market darling and can get a valuation above a billion dollar Mcap !

Its a Unicorn in making !

Please DYOR

ALL IMO

Stay Safe

Bhavdip